Residents' Association Werdenberg


Managing Side Effects of Vardenafil 5 mg

Other > vardenafil 5 mg


These observations should be considered in clinical decisions when prescribing LEVITRA to patients with known

Adverse Effects

Long-term safety information is not available on the concomitant administration of vardenafil with HIV protease inhibitors. Concomitant administration with ritonavir or indinavir substantially increases plasma concentrations of vardenafil. Because ritonavir prolongs LEVITRA elimination half-life (5 to 6-fold), no more than a single 2.5 mg dose of LEVITRA should cenforce 200 uk be taken in a 72-hour period by patients also taking ritonavir. Patients taking indinavir, saquinavir, atazanavir or other potent CYP3A4 inhibitors such as clarithromycin, ketoconazole 400 mg daily, or itraconazole 400 mg daily should not exceed a dose of LEVITRA 2.5 mg once daily. For patients taking ketoconazole 200 mg daily or itraconazole 200 mg daily, a single dose of 5 mg LEVITRA should not be exceeded in a 24-hour period (see PRECAUTIONS,Drug Interactions and DOSAGE AND ADMINISTRATION).

Can vardenafil and tadalafil be taken together?

There have been rare reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds, including vardenafil. In the event that an erection persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. There are no controlled clinical data on the safety or efficacy of LEVITRA in the following patients; and therefore its use is not recommended until further information is available. unstable angina; hypotension (resting systolic blood pressure of <90 mmHg); uncontrolled hypertension (>170/110 mmHg); recent history of stroke, life-threatening arrhythmia, or myocardial infarction (within the last 6 months); severe cardiac failure known hereditary degenerative retinal disorders, including retinitis pigmentosa The evaluation of erectile dysfunction should include a determination of potential underlying causes, a medical assessment, and the identification of appropriate treatment. history of QT prolongation or patients who are taking medications known to prolong the QT interval.

Step Description Tips
Taking the medication Take orally with a glass of water Can be taken with or without food
Timing before sexual activity 30-60 minutes prior Avoid heavy fatty meal initially
Duration of effect Up to 4-5 hours, depending on individual Be aware of your response
Do not exceed prescribed dose Usually 5 mg per dose, once per day Overdose risks and side effects

amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation, should avoid using LEVITRA.

Product Dosage Quantity + Bonus Price
Cialis Generic2.5mg360 + 10 Pills260.03€ 247.65€
Viagra Generic200mg10 Pills40.96€ 39.01€
Cialis Generic2.5mg60 + 4 Pills83.43€ 79.46€
Cialis Generic2.5mg90 + 6 Pills112.43€ 107.08€
Apcalis SX Oral Jelly20mg10 Sachets58.75€ 55.95€
Kamagra 100 mg100 mg180 + 6 Pills436.79€ 415.99€
Viagra Super Active100mg20 + 4 Pills48.05€ 45.76€
Cialis Generic60mg10 Pills41.22€ 39.26€
Viagra Super Active100mg120 + 16 Pills198.37€ 188.92€
Kamagra Polo100 mg120 + 6 Pills327.15€ 311.57€
Kamagra Gold100 mg120 + 6 Pills330.74€ 314.99€
Apcalis SX Oral Jelly20mg50 + 6 Sachets146.39€ 139.42€
Kamagra Effervescent Tablets100 mg14 Pills51.61€ 49.15€
Viagra Original100mg48 + 4 Pills207.15€ 197.29€
Cialis Professional40mg120 + 4 Pills436.68€ 415.89€
Super Kamagra160 mg20 + 4 Pills155.35€ 147.95€
Priligy Generic Dapoxetine60mg10 Pills47.63€ 45.36€

In patients with moderate (CLcr = 30-50 ml/min) to severe (CLcr<30

Product Description

Before prescribing LEVITRA, it is important to note the following: Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. Phosphodiesterase Type 5 (PDE5) inhibitors, including LEVITRA, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly (see PRECAUTIONS,Drug Interactions) leading to symptomatic hypotension (e.g., fainting). Consideration should be given to the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.

What are the side effects of vardenafil?

Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest recommended starting dose (see DOSAGE and ADMINISTRATION). In those patients already taking an optimized dose of PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in lovegra women patients taking a PDE5 inhibitor. Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs. ml/min) renal impairment, the AUC of vardenafil was 20 – 30%

Disclosure statement

In the North American trial, LEVITRA significantly improved the rates of achieving an erection sufficient for penetration (SEP2) at doses of 5 mg, 10 mg, and 20 mg compared to placebo (65%, 75%, and 80%, respectively, compared to a 52% response in the placebo group at 3 months; p <0.0001). LEVITRA demonstrated a clinically meaningful and statistically significant increase in the overall per-patient rate of maintenance of erection to successful intercourse (SEP3) (51% on 5 mg, 64% on 10 mg, and 65% on 20 mg, respectively, compared to 32% on placebo; p <0.0001) at 3 months in the North American trial. This improvement in mean score was maintained at all doses at 6 months in the North American trial. Trial in Patients with ED and Diabetes Mellitus: LEVITRA demonstrated clinically meaningful and statistically significant improvement in erectile function in a prospective, fixed-dose (10 and 20 mg LEVITRA), double-blind, placebo-controlled trial of patients with diabetes mellitus (n=439; mean age 57 years, range 33-81; 80% White, 9% Black, 8% Hispanic, and 3% Other). Significant improvements in the EF Domain were shown in this study (EF Domain scores of 17 on 10 mg LEVITRA and 19 on 20 mg LEVITRA compared to 13 on placebo; p <0.0001).

Other Medical Problems

LEVITRA significantly improved the overall per-patient rate of achieving an erection sufficient for penetration (SEP2) (61% on 10 mg and 64% on 20 mg LEVITRA compared to 36% on placebo; p <0.0001). LEVITRA demonstrated a clinically meaningful and statistically significant increase in the overall per-patient rate of maintenance of erection to successful intercourse (SEP3) (49% on 10 mg, 54% on 20 mg LEVITRA compared to 23% on placebo; p <0.0001). Trial in Patients with ED after Radical Prostatectomy: LEVITRA demonstrated clinically meaningful and statistically significant improvement in erectile function in a prospective, fixed-dose (10 and 20 mg LEVITRA), double-blind, placebo-controlled trial in post-prostatectomy patients (n=427, mean age 60, range 44-77 years; 93% White, 5% Black, 2% Other). Significant improvements in the EF Domain were shown in this study (EF Domain scores of 15 on 10 mg LEVITRA and 15 on 20 mg LEVITRA compared to 9 on placebo; p <0.0001). LEVITRA significantly improved the overall per-patient rate of achieving an erection sufficient for penetration (SEP2) (47% on 10 mg and 48% on 20 mg LEVITRA compared to 22% on placebo; p <0.0001). higher compared to that observed in a control group with normal

What should I avoid while using vardenafil?

In volunteers with moderate impairment (Child-Pugh B), the Cmax and AUC following a 10 mg vardenafil dose were increased 130% and 160%, respectively, compared to healthy control subjects. Consequently, a starting dose of 5 mg is recommended for patients with moderate hepatic impairment and the maximum dose should not exceed 10 mg (see CLINICAL PHARMACOLOGY,Pharmacokinetics in Special Populations, and DOSAGE AND ADMINISTRATION). Vardenafil has not been evaluated in patients with severe hepatic impairment (Child-Pugh C). Congenital or Acquired QT Prolongation: In a study of the effect of LEVITRA on QT interval in 59 healthy males (see CLINICAL PHARMACOLOGY,Electrophysiology), therapeutic (10 mg) and supratherapeutic (80 mg) doses of LEVITRA and the active control moxifloxacin (400 mg) produced similar increases in QTc interval. A postmarketing study evaluating the effect of combining LEVITRA with another drug of comparable QT effect showed an additive QT effect when compared with either drug alone (see CLINICAL PHARMACOLOGY,Electrophysiology). renal function (CLcr>80 ml/min) (see CLINICAL PHARMACOLOGY, Pharmacokinetics in Special Populations).

  • Vardenafil 5 mg is used to treat erectile dysfunction in men.
  • It works by increasing blood flow to the penis.
  • Vardenafil 5 mg usually starts working within 30-60 minutes.
  • The typical dosage for Vardenafil 5 mg is once daily.
  • It is available by prescription only.
  • Vardenafil 5 mg may cause side effects like headache or flushing.
  • It is more effective when taken on an empty stomach.
  • Alcohol can increase the risk of side effects with Vardenafil.
  • Do not take Vardenafil 5 mg with nitrates or certain medications.
  • Store Vardenafil 5 mg in a cool, dry place away from children.
  • Consult your doctor before starting Vardenafil 5 mg.
  • Report any persistent or severe side effects to your doctor.

Vardenafil pharmacokinetics have not been evaluated in patients requiring renal dialysis.

  • Vardenafil 5 mg is effective in treating primary and secondary ED.
  • It is marketed under various brand names worldwide.
  • Generic Vardenafil 5 mg is usually more affordable.
  • It is not suitable for individuals with certain eye conditions.
  • Possible side effects include nasal congestion or dizziness.
  • Use with caution if you have kidney or liver issues.
  • Consultation with a healthcare provider is essential before use.
  • Vardenafil 5 mg does not provide protection from sexually transmitted infections.
  • Keep medical records updated when taking this medication.
  • Never share your medication with others.
  • It is important to have realistic expectations about treatment.
  • Follow-up appointments help monitor efficacy and safety.

General: In humans, vardenafil alone in doses up to 20 mg does not prolong the bleeding time.

Side Effect Frequency Severity Management Tips
Headache Common Mild to Moderate Hydration, OTC pain relief
Flushing Frequently reported Mild Cool environment, calming techniques
Nasal congestion Sometimes Mild Decongestants (if advised)
Dizziness Occasionally Mild Sit or lie down, avoid driving
Upset stomach Less common Mild Take with food, monitor symptoms

There is no clinical evidence of any additive prolongation of the bleeding time when vardenafil is administered with aspirin.

  • Vardenafil 5 mg is a PDE5 inhibitor for erectile dysfunction.
  • It helps men achieve and maintain an erection suitable for intercourse.
  • Vardenafil 5 mg is often prescribed when other treatments fail.
  • This medication can be taken with or without food.
  • The effects of Vardenafil 5 mg last about 4-6 hours.
  • It is important to follow your healthcare provider’s instructions.
  • Avoid high-fat meals close to taking Vardenafil for faster effect.
  • Combining Vardenafil 5 mg with recreational drugs is dangerous.
  • It may interact with blood pressure medications.
  • Do not exceed the prescribed dose to prevent risks.
  • Vardenafil 5 mg is generally well-tolerated.
  • Always check for contraindications before use.

Vardenafil has not been administered to patients with bleeding disorders or significant active peptic ulceration.

Dose Adjustments

LEVITRA demonstrated a clinically meaningful and statistically significant increase in the overall per-patient rate of maintenance of erection to successful intercourse (SEP3) (37% on 10 mg, 34% on 20 mg LEVITRA compared to 10% on placebo; p <0.0001). Nitrates: Administration of LEVITRA with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated (see CLINICAL PHARMACOLOGY, Pharmacodynamics, Effects on Blood Pressure and Heart Rate when LEVITRA is Combined with Nitrates). Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates. A suitable time interval following LEVITRA dosing for the safe administration of nitrates or nitric oxide donors has not been determined. Hypersensitivity: LEVITRA is contraindicated for patients with a known hypersensitivity to any component of the tablet.

Usual Geriatric Dose for:

General: Physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. In men for whom sexual activity is not recommended because of their underlying cardiovascular status, any treatment for erectile dysfunction, including LEVITRA, generally should not be used. Left Ventricular Outflow Obstruction: Patients with left ventricular outflow obstruction, e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis, can be sensitive to the action of vasodilators including Type 5 phosphodiesterase inhibitors. Blood Pressure Effects: LEVITRA has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 7 mmHg systolic and 8 mmHg diastolic) (see CLINICAL PHARMACOLOGY, Pharmacodynamics). While this normally would be expected to be of little consequence in most patients, prior to prescribing LEVITRA, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects.